NYU Langone Medical Center's tip sheet to the 44th annual meeti...(with a new type of agent that releases m...),Health

Abstract # 3044 : KBMA Listeria monocytogenes is an effective antigen loading platform for dendritic cell-mediated induction of anti-tumor immunity
NYU Cancer Institutes Nina Bhardwaj, M.D., professor of medicine, pathology, dermatology; director, tumor vaccine program, at NYU Langone Medical Center
NYU Cancer Institutes Mojca Skoberne, Ph.D. researcher, at NYU Langone Medical Center

NYU Langone Medical Center researchers report that killed but metabolically active recombinant Listeria monocytogenes, a Gram-positive bacterium, may provide a platform for novel melanoma vaccines. Melanoma is the deadliest form of skin cancer, and will afflict some 62,480 people in the United States this year. The researchers demonstrate in an animal model and in vitro human cell cultures that immune cells were called into action by tumor proteins expressed by the bacterium. The finding suggests that the genetically engineered bacterium may be used to bolster the immune response against a resurgence of the deadly cancer. Clinical trials are underway at the medical center using a melanoma vaccine that employs powerful immune cells called dendritic cells. The bacterial approach to activate the dendritic cells may provide a new avenue for developing a more powerful cancer vaccine.

A phase I/II study to determine the feasibility and efficacy of the triple combination of oblimersen (OBL), abraxane (ABX), and temozolomide (TMZ) in metastatic melanoma and normal LDH
NYU Cancer Institutes Anna C Pavlick, D.O., assistant professor of medicine and dermatology at NYU Langone Medical Center; co-program leader, melanoma research program

Researchers at NYU Langone Medical Center report
'/>"/>